Skip to main content

Drug Interactions between edaravone and ezogabine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ezogabine edaravone

Applies to: ezogabine and edaravone

MONITOR: Coadministration with inhibitors of the uptake transporters organic anion transporter 1 and/or 3 (OAT1, OAT3) may increase the plasma concentration of edaravone sulfate, the active metabolite of edaravone, which is a substrate for these transporters. However, data from in vivo studies are lacking.

MANAGEMENT: Caution is advised if edaravone is used concomitantly with OAT1 and/or OAT3 inhibitors. Dosage adjustments as well as clinical monitoring of edaravone therapy should be considered whenever an OAT1 and/or OAT3 substrate is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.

References (1)
  1. (2023) "Product Information. Radicava (edaravone)." Teva Pharma Australia Pty Ltd

Drug and food interactions

Moderate

ezogabine food

Applies to: ezogabine

GENERALLY AVOID: Alcohol may increase the plasma concentrations of ezogabine. In a study of healthy volunteers, the administration of ezogabine 200 mg in combination with ethanol 1g/kg (5 standard alcohol drinks) over 20 minutes resulted in an increase in the ezogabine peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 37%, respectively.

Food does not significantly affect the bioavailability of ezogabine. According to the product labeling, high-fat food does not affect the extent to which ezogabine is absorbed, but increases peak plasma concentration (Cmax) by approximately 38% and delays the time to reach peak concentration (Tmax) by 0.75 hour.

MANAGEMENT: In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents. Patients should be advised of the potential for increased dose-related adverse reactions of ezogabine (e.g., dizziness, somnolence, nausea, constipation, urinary retention, blurred vision, memory impairment, tremor) when taken with alcohol, and to avoid hazardous activities that require mental alertness and motor coordination until they know how the medication affects them. Ezogabine can be taken with or without food.

References (1)
  1. (2011) "Product Information. Potiga (ezogabine)." GlaxoSmithKline

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer